Q-omics provides the consensus-scored REV3L profile across patient tissues and cancer cell-line models. REV3L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, REV3L is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, REV3L RNA expression shows 22,123 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where REV3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REV3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REV3L survival associations across molecular data types. REV3L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REV3L RNA expression–survival associations across cancer types. High REV3L expression shows unfavorable associations in BLCA, ACC and KICH, but favorable associations in KIRC, HNSC and GBM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for REV3L RNA expression.
This table summarizes REV3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for REV3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REV3L shows lower tumor expression in KICH, THCA, LUAD, BRCA and LUSC and higher tumor expression in HNSC. The HNSC box plot shows higher REV3L RNA expression in tumor versus normal tissue (log2 FC = +0.621, t-test p < 0.001).
This table shows molecular features associated with REV3L in patient tissues and cancer cell lines. In patient samples, REV3L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, REV3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
